ArticleScientific reports2026
Circulating matrix metalloproteinase profile in early-stage primary biliary cholangitis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease with progressive bile duct injury, inflammation, and fibrosis. Matrix metalloproteinases (MMPs) contribute to extracellular matrix remodeling but their circulating profile and clinical relevance in early-stage PBC remain incompletely defined. We characterized circulating MMPs in early-stage PBC and related them to non-invasive fibrosis and portal hemodynamics. Forty-six patients with early-stage PBC and 31 healthy controls were studied. Plasma MMP-2, -3, -7, -9, -10, and -26 were quantified by ELISA; liver stiffness was measured by point shear-wave elastography and portal flow indices by Doppler ultrasound. Compared with controls, PBC patients showed higher MMP-7 (p < 0.0001), MMP-2 (p = 0.0007), and MMP-10 (p = 0.046). MMP-7 correlated with liver stiffness (R = 0.68, p < 0.001) and demonstrated the highest discriminatory performance for significant fibrosis defined as LSM > 5.56 kPa (AUC = 0.800, p < 0.001). In exploratory regression analyses, higher MMP-7 concentrations remained associated with significant fibrosis after adjustment for age, whereas APRI and FIB-4 did not show significant discriminatory performance in ROC analysis. Early-stage PBC is therefore associated with a distinct plasma MMP profile, and MMP-7 may serve as a practical biomarker of fibrogenesis, supporting its use for monitoring disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.